American Century Companies Inc. Acquires 20,901 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

American Century Companies Inc. boosted its holdings in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) by 56.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,252 shares of the company’s stock after acquiring an additional 20,901 shares during the period. American Century Companies Inc.’s holdings in Pyxis Oncology were worth $193,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Pier 88 Investment Partners LLC lifted its holdings in Pyxis Oncology by 121.4% during the second quarter. Pier 88 Investment Partners LLC now owns 113,700 shares of the company’s stock worth $376,000 after acquiring an additional 62,340 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Pyxis Oncology in the second quarter valued at about $216,000. Bank of New York Mellon Corp lifted its holdings in shares of Pyxis Oncology by 92.2% in the second quarter. Bank of New York Mellon Corp now owns 311,630 shares of the company’s stock valued at $1,031,000 after purchasing an additional 149,522 shares in the last quarter. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology in the second quarter valued at about $40,000. Finally, Cetera Advisors LLC bought a new stake in shares of Pyxis Oncology in the first quarter valued at about $100,000. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Stock Performance

NASDAQ:PYXS opened at $3.54 on Friday. The stock’s 50-day simple moving average is $3.58 and its 200 day simple moving average is $3.86. The company has a market cap of $208.46 million, a P/E ratio of -2.60 and a beta of 1.27. Pyxis Oncology, Inc. has a 52-week low of $1.35 and a 52-week high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. As a group, equities analysts predict that Pyxis Oncology, Inc. will post -1.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on PYXS shares. Stifel Nicolaus started coverage on Pyxis Oncology in a report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Friday, August 16th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Buy” and an average target price of $9.00.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.